There is a wide variety of auto-antibodies found in the serum of patients with Sjogren's syndrome. Table 1 gives the incidence of certain auto-antibodies in Sjogren's syndrome as found by Dr Deborah Doniach and myself in a recent survey. The rheumatoid factor was found in 82 %, and was present in the same proportion of cases without as with joint involvement, showing that the term 'rheumatoid factor' is misleading. The auto-immune complement-fixation test (A.l.C.F.) was done against salivary and lacrimal gland, liver and kidney. Tests for thyroid auto-antibodies were done as described by Hymans et al. (1961) . The serum of patients with Sjogren's syndrome therefore contains both organ-specific as well as non-organ-specific auto-antibodies. Table 1 also shows that the pattern is more closely allied to that of systemic lupus and rheumatoid arthritis than to that of Hashimoto's disease. This pattern parallels the clinical picture, which is that of a disease with a tendency for several systems to be affected, in contrast to Hashimoto's disease where usually only the thyroid is diseased.
The auto-immune diseases can be viewed as forming a spectrum. In many cases only one part of the spectrum is involved, as in Hashimoto's disease and discoid lupus. In others several tissues are affected, as in Sj6gren's syndrome.
Occasionally there is massive involvement of many tissues, as in acute systemic lupus erythematosus.
Treatment of the condition is unsatisfactory. Systemic steroids are not often helpful. Antimalarials, mainly hydroxychloroquine, help some cases. It is usually necessary to resort to local palliative measures such as the use of artificial tears and sealing of the puncta.
Introduction
Attempts have been made to reduce serum cholesterol in three ways: (1) Reduction of dietary fat. (2) Increased catabolism and excretion of cholesterol by the biliary and intestinal tract. (3) Diminished endogenous biosynthesis of cholesterol, mainly in the liver.
Endogenous biosynthesis is by far the most important source of cholesterol and is capable of replacing dietary deficiency or increased excretion. Inhibition of biosynthesis is then likely to be the most effective method of lowering the serum cholesterol.
MER-291 is a synthetic compound discovered in the course of the development of the synthetic cestrogens, but having no feminizing effects (Palopoli 1960) . It has been shown to block the synthesis of cholesterol by inhibition of reduction of the 24-25 double bond at the stage of conversion of desmosterol (24-dehydrocholesterol) to cholesterol.
In patients on MER-29 therapy there is a reduction of the serum cholesterol, but this has been found to be associated with an accumulation of desmosterol in the serum (Frantz et al. 1960 ). Most methods of cholesterol estimation (including that used in this experiment) depend on the development of a colour reaction with the Liebermann-Burchard reagent. Desmosterol also reacts with this reagent, but produces only 600% of the colour yield of cholesterol ). There is therefore a greater reduction of cholesterol than indicated by this method, and, similarly, the level of total sterol (cholesteroldesmosterol) is higher. This fact has only recently been appreciated fully and most studies have reported changes in cholesterol which are in fact a mixture of change in cholesterol and desmosterol (Oaks et al. 1959 , Estes 1960 , Rosenman & Friedman 1960 , Ruskin & Ruskin 1960 . The sterol as measured by the Liebermann-Burchard reaction will be referred to as the apparent cholesterol.
In this study has been used to lower the cholesterol in 15 hypercholesterolkmic patients with xanthomatosis or ischaemic heart disease, in an attempt to assess the clinical value of the drug. 
Methods
Patients: The clinical findings in the 15 patients studied are set out in Table 1 . All had hypercholesteroltemia (>300 mg/100 ml) and 7 had xanthomatosis. Thirteen had ischvmic heart disease and 4 had a previous history of myocardial infarction. The severity of the angina was graded, Grade 1 being the least severe and Grade 4 the most (Wood 1956 ). Electrocardiographic evidence of myocardial ischemia (depression S-T, inversion T) was present in 9 patients, and in addition one had a bundle branch block, another 2 :1 heart block. Hypertension (blood pressure > 160/90 mm Hg) was present in 3 patients and in 3 there was intermittent claudication, the severity of which was also graded (Boyd 1954) . Before treatment the patients were seen regularly over a period of several months, when the severity of their symptoms was assessed and xanthomata measured with calipers. Treatment was then started with MER-29, 250 mg each morning. The dose was increased to 500 mg/day when the reduction of apparent cholesterol was inadequate. The intention was to maintain treatment for one year (Table 2) . Nine patients were treated for more than eleven months; 3 died and the drug was withdrawn in 3 patients.
Total serum cholesterol: This was estimated by Method 1 of Billimoria & James (1960) . Cholesterol was extracted from serum with a mixture of acetone-alcohol. An aliquot of the extract was evaporated to dryness and the Liebermann-Burchard colour reaction was performed on the residue in glacial acetic acid. The estimation was repeated at least monthly in the control and treatment periods.
Other investigations: Liver function tests were carried out at the beginning and end of treatment.
The tests were: total bilirubin, alkaline phosphatase, total protein, thymol turbidity and flocculation, colloidal gold, mercuric chloride, serum glutamate oxaloacetate and pyruvate transaminase. The urinary 17-ketosteroids and 1 7-hydroxycorticosteroids, serum electrolytes, urea and blood count were also measured during the control and treatment periods.
Results
Ischwemic heart disease (Table 2 ): In the 7 patients with xanthomatosis 3 developed a myocardial infarct, which was fatal in 2, while on treatment with MER-29. Angina increased in 2 others, necessitating withdrawal of the drug in one.
In the 8 non-xanthomatous patients one died of myocardial infarction while on MER-29. Angina increased in Case 1, necessitating withdrawal of the drug, but it was reintroduced and at the end of the trial her angina was unaltered. There was no change in angina in 3 other patients and this symptom diminished in a further 3 patients, but the improvement was slight and remained within the same grade of severity.
Xanthomata (Table 2) : There was diminution in the size of xanthomata in only one patient, in whom the xanthoma tuberosum became smaller. Table 2 The effect of treatment on 15 hypercholesterolemic patients ( Mean -4 41
Hair loss. Loss libido 0, no effect; +, increased; -, diminished; M.I., myocardial infarct.;
Toxic effects (Table 2) : Three patients complained of constipation, 3 of nausea, 2 of loss of scalp hair, 1 of a transient rash, 1 of dry skin and 1 of loss of libido. There was loss of weight in 10 patients, with a mean fall of 41-lb for all patients. The serum alkaline phosphatase rose to an abnormal level in Cases 3, 5, 10 and 11. No reduction of the urinary 17-ketosteroids or 17-hydroxycorticosteroids occurred. The serum electrolytes, urea and blood-count were unaffected by MER-29. (Table 3) : The average total serum cholesterol during the control period was calculated for each patient, the mean value for all patients being 428 mg/100 ml. Similarly, the average apparent serum cholesterol for each patient during the treatment period was found and the mean value was 358 mg/100 ml. As a result of treatment, there was a significant mean reduction of 70 mg/100 ml of the apparent cholesterol or a fall of 16 % if expressed as a percentage of the control total cholesterol. The fall varied between 6% and 39%, but in 2 patients with xanthomatosis who died of myocardial infarction there was a rise of 8 % and 17 %.
Serum total cholesterol
The monthly change in the cholesterol is shown in Fig 1. The reduction continued up to the fifth month of treatment and there was, thereafter, little fall, although the number of patients studied was by then smaller. The effect of the drug was Alk. P, alkaline phosphatase maintained and there was no evidence of escape of the cholesterol towards previous levels.
Discussion
Ischwmic heart disease: Three fatal and one nonfatal myocardial infarct with increasing angina necessitating withdrawal of the drug in two Table 3 The effect of treatment on serum total cholesterol (Cases 9-15 with xanthomatosis) o-0 mean patients, out of a total of 15 treated, is a disturbing result, although it must not be forgotten that the prognosis in these patients is poor. Earlier studies have reported improvement in angina, but the detailed facts of this variable symptom are generally not given (Lisan 1960 , Halperin 1960 ). An improvement in the electrocardiographic findings after the standard exercise tolerance test has been found in a few patients (Hollander & Chobanian 1959) . When improvement has been found the angina was generally of recent onset (less than four years) and there is a suggestion that MER-29 may act as a coronary vasodilator (Halperin 1960) . The question arises whether MER-29 is affecting the patients adversely, for in 2 xanthomatous patients the apparent cholesterol rose before a fatal myocardial infarct. The relation of desmosterol to atherosclerosis is unknown and this substance accumulates in the blood and may well appear in the tissues, as it does in those of animals . Desmosterol resembles cholesterol closely in its physical properties, distribution in the lipoprotein fractions, rates of esterification, and ratio of free to ester form (Steinberg et al. 1961) . It is possible that on MER-29 therapy another atherogenic substance may be in part replacing the reduced body cholesterol.
Xanthomata: There was no reduction in the size of xanthomata in this trial, apart from slight diminution in xanthoma tuberosum in one patient. There was no effect on xanthomata in 5 patients described by Jose et al. (1961) , but one report mentions, unconvincingly, a reduction in size of xanthelasma (Corcoran 1961) . The failure of xanthomata to shrink does not necessarily imply that fat has not been removed from the lesion, for xanthomata tendinosum contain a high proportion of fibrous tissue.
Serum total cholesterol: The present trial has shown a small reduction of 16% (70 mg/100 ml) in the mean apparent cholesterol, and it is now known that although the reduction in true cholesterol would be greater the reduction of total sterol would be smaller. In patients with xanthomatosis the reduction of 8 % was even smaller and in 2 patients the apparent cholesterol rose. In xanthomatosis rise in the total sterol in 1 patient (Steinberg et al. 1961 ) and of the apparent cholesterol in 3 (Hall 1961 ) has been noted previously. Methods have been found by which changes in actual cholesterol and desmosterol can be followed, although there is some divergence of opinion on these , Frantz et al. 1960 , Jose et al. 1961 , Sachs & Wolfman, 1961 . On treatment with MER-29 the true cholesterol has been found to fall by 34 % with an accumulation of desmosterol (25-55 mg/100 ml) and hence a fall in the total sterol of only 15 % (Steinberg et al. 1961) .
A dose of 250-500 mg/day of MER-29 has been found to be as effective as greater quantities in lowering the apparent cholesterol (Oaks 1960) . Some studies have reported a tendency for the apparent cholesterol to rise on continued therapy (Gould 1960 , Toro 1960 , Waddell 1960 , Ruskin & Ruskin 1960 and an initial rise in the level early in therapy has also been described (Kountz 1960 , Estes 1960 ) but neither of these effects has been seen in the present trial.
The question arises whether the reduction of serum sterols is associated with an accumulation of sterol in the tissues. Radioisotopic studies show that the total body sterol is reduced by MER-29 (Hollander et al. 1960 ) and that desmosterol accumulates in the serum, but this rise does not continue and a steady level is reached. This is probably due to the ability of the liver to metabolize desmosterol via the bile acids in the same way as cholesterol (Blohm et al. 1960 , Goodman et al. 1961 .
Toxicity: Elevation of the serum alkaline phosphatase due to MER-29 has been found in 4 patients and a similar disturbance of liver function has been reported previously (Hollander et al. 1960 , Leckert et al. 1960 , Oaks 1960 . The patients had no symptoms of liver disorder and the effect is reversible on reducing or withdrawing * .3~~~~~~--I the drug. A dermatitis necessitating withdrawal of the drug has been described (Hollander et al. 1960 , Oaks 1960 and 2 patients in this trial had transient skin disorders. A more serious dermatitis complicated by hair changes and cataract in 4 patients on normal doses of MER-29 has recently been reported (Mansell-Jones 1962, personal communication). Two patients complained of loss of scalp hair which has been described, and so, surprisingly, has re-growth (Toro 1960) . Diminished libido has been reported (Kountz 1960) and this occurred in one of the male patients. Nausea and constipation were frequent complaints, though not necessitating withdrawal of the drug unless the dose was high (Hollander et al. 1960 , Oaks 1960 . Other toxic effects reported have been leucopenia (Oaks 1960) , reduction of urinary corticosteroid excretion (Hollander & Chobanian 1959) and temporary post-menopausal bleeding (Toro 1960) , but none of these has been observed in this trial.
Summary and Conclusions
Fifteen patients with hypercholesterolhmia and ischemic heart disease or xanthomatosis were treated with MER-29 (triparanol) for periods of between two and fifteen months. Four patients developed a myocardial infarct and in 3 this was fatal. There was no evidence of any improvement in angina, and the drug was discontinued in 2 patients, because of increase in this symptom. No significant diminution of xanthomata was found.
Minor toxic effects occurred, with elevation of alkaline phosphatase in 4 patients. Serious skin changes with cataract formation were not observed.
The apparent serum cholesterol, as measured by the Leibermann-Burchard reaction, was reduced by only 160% on treatment. This implies an even smaller reduction of total sterol, due to the accumulation of demosterol in the serum. The apparent cholesterol rose in-2 patients with xanthomatosis who died of myocardial infarction.
It is concluded that MER-29 is not suitable for the general treatment of ischkmic heart disease or xanthomatosis until the atherogenic properties of desmosterol are known.1
